Hepatocellular carcinoma

• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 "Advanced or metastatic solid tumors"
• An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporo … Ended
  2024-514496-18-01 3 2025-01-30 "Hepatocellular carcinoma, renal cell carcinoma and different"
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C … Ended
  2022-502840-11-00 9 2023-11-28 "Hepatocellular Carcinoma (Morpheus-Neo HCC)"
• A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Ended
  2023-504400-29-00 1 2022-09-15 "Advanced malignancies."
• A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo … Ended
  2024-511750-53-00 7 2022-09-08 "Unresectable Locally Advanced or Metastatic Cancer"
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 9 2022-09-02 "Advanced/metastatic hepatocellular carcinoma (HCC)"
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Ended
  2023-505425-14-00 9 2022-08-11 "colorectal cancer"
• A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SU … Ended
  2024-516290-67-00 9 2022-08-03 "ADVANCED SOLID TUMORS AND LYMPHOMA"
• A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 … Ended
  2024-516289-12-00 9 2022-02-24 "Endometrial cancer, Ovarian cancer, Biliary tract cancer, He"
• Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca … Ended
  2024-513707-14-00 5 2022-01-14 "Only patients with oncologic locally advanced or metastatic "
• A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno- … Ended
  2023-503519-13-00 4 2020-12-14 "Advanced Hepatocellular Carcinoma"
• A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous niv … Ended
  2023-506156-25-00 9 2020-11-13 "Advanced hepatocellular carcinoma"
• Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended
  2022-502116-36-00 5 2020-07-10 "Incurable/Non-metastatic Hepatocellular Carcinoma"
• Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune ch … Ended
  2024-516972-14-00 4 2020-01-30
• Study of subcutaneous nivolumab monotherapy with or without Recombinant Human Hyaluronidase PH20 (rHuPH20) Ended
  2023-503554-12-00 9 2019-01-09 "lung cancer; kidney cancer; melanoma; liver cancer; colorect"
• Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended
  2023-508067-70-00 9 2015-04-15 "Neoplasms by site"
• A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors Ended
  2023-503243-34-00 3 "Solid tumor"

Showing 25–41 of 41 trials